文献速递肝肾功能剂量调整特殊人群用药

依诺肝素儿童群体药代动力学特征助力剂量个体化

Characterizing Enoxaparin's Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population.
PubMed 文献 · Clin Pharmacokinet · 2024-07-02

本研究利用1293例1天至18岁儿童的抗Xa数据建立依诺肝素群体药代动力学模型,发现血清肌酐显著影响清除率,模拟显示2岁以下按总体重1.5 mg/kg给药可达治疗浓度,2岁以上按去脂体重1.0 mg/kg给药可使肥胖与非肥胖儿童暴露更接近。

要点

  • 2岁以下儿童按总体重1.5 mg/kg给药可达治疗浓度
  • 2岁以上儿童按去脂体重1.0 mg/kg给药可减少肥胖儿童过量风险
  • 血清肌酐是依诺肝素清除率的显著协变量

核心结论

  • 依诺肝素在儿童中的药代动力学特征可通过包含异速增长和血清肌酐协变量的线性一室模型描述。
  • 使用去脂体重和每日两次给药可能降低过量风险,尤其对肥胖儿童。

研究设计与样本

  • 基于1293例年龄1天至18岁儿童的真实世界抗Xa数据,采用NONMEM进行群体药代动力学分析。
  • 采用逐步协变量建模方法筛选协变量,最终模型模拟预防和治疗剂量下的皮下给药暴露。

主要发现

  • 最终模型为线性一室模型,采用总体重(<2岁)或去脂体重(≥2岁)的异速增长 scaling。
  • 血清肌酐被确定为影响清除率的显著协变量。
  • 模拟显示<2岁患者按总体重1.5 mg/kg给药可达治疗浓度。
  • ≥2岁患者按去脂体重1.0 mg/kg给药时,肥胖与非肥胖儿童暴露更可比。

关键数值与推荐

  • 推荐剂量:<2岁按总体重1.5 mg/kg;≥2岁按去脂体重1.0 mg/kg。
  • 肥胖定义为体重指数百分位≥95th百分位。

临床怎么用

  • 临床可根据年龄选择总体重或去脂体重计算依诺肝素剂量以优化儿童抗凝治疗。
  • 对肥胖儿童使用去脂体重和每日两次给药可能降低过量风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Pediatric dosing of enoxaparin was derived based on extrapolation of the adult therapeutic range to children. However, a large fraction of children do not achieve therapeutic anticoagulation with initial dosing. We aim to use real-world anti-Xa data obtained from children receiving enoxaparin per standard of care to characterize the population pharmacokinetics (PopPK) METHODS: A PopPK analysis was performed using NONMEM, and a stepwise covariate modeling approach was applied for the covariate selection. The final PopPK model, developed with data from 1293 patients ranging in age from 1 day to 18 years, was used to simulate enoxaparin subcutaneous dosing for prophylaxis and treatment based on total body weight (0-18 years, TBW) or fat-free mass (2-18 years, FFM). Simulated exposures in children with obesity (body mass index percentile ≥95th percentile) were compared with those without obesity. RESULTS: A linear, one-compartment PopPK model that included allometric scaling using TBW (<2 years) or FFM (≥2 years) characterized the enoxaparin pharmacokinetic data. In addition, serum creatinine was identified as a significant covariate influencing clearance. Simulations indicated that in patients aged <2 years, the recommended 1.5 mg/kg TBW-based dosing achieves therapeutic simulated concentrations. In pediatric patients aged ≥2 years, the recommended 1.0 mg/kg dose resulted in exposures more comparable in children with and without obesity when FFM weight-based dosing was applied. CONCLUSION: Using real-world data and PopPK modeling, enoxaparin's pharmacokinetics were characterized in pediatric patients. Using FFM and twice-daily dosing might reduce the risk of overdosing, especially in children with obesity.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Carreño FO, Gerhart JG, Helfer VE, et al. Characterizing Enoxaparin's Population Pharmacokinetics to Guide Dose Individualization in the Pediatric Population. Clin Pharmacokinet. 2024. PMID: 38955947. doi:10.1007/s40262-024-01388-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。